Xizang Haisco Pharmaceutical Group Co Ltd (002653) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.009x

Based on the latest financial reports, Xizang Haisco Pharmaceutical Group Co Ltd (002653) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥39.68 Million ≈ $5.81 Million USD) by net assets (CN¥4.23 Billion ≈ $618.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Xizang Haisco Pharmaceutical Group Co Lt free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.

Xizang Haisco Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see 002653 market cap for the company's overall valuation and market capitalisation.

Xizang Haisco Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xizang Haisco Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
First Horizon Corporation
NYSE:FHN
0.029x
MOL Nyrt.
BUD:MOL
0.046x
VERBUND AG
VI:VER
0.039x
Evercore Partners Inc
NYSE:EVR
-0.108x
Regal Beloit Corporation
NYSE:RRX
0.024x
Littelfuse Inc
NASDAQ:LFUS
0.031x
Datang International Power Generation Co Ltd Class A
SHG:601991
0.290x
Hong Leong Bank Bhd
KLSE:5819
0.055x

Annual Cash Flow Conversion Efficiency for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025. View 002653 stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥4.29 Billion
≈ $627.44 Million
CN¥786.00 Million
≈ $115.02 Million
0.183x +74.26%
2024-12-31 CN¥4.20 Billion
≈ $614.92 Million
CN¥442.05 Million
≈ $64.69 Million
0.105x -2.42%
2023-12-31 CN¥4.17 Billion
≈ $610.28 Million
CN¥449.58 Million
≈ $65.79 Million
0.108x +257.25%
2022-12-31 CN¥3.13 Billion
≈ $458.49 Million
CN¥94.55 Million
≈ $13.84 Million
0.030x +146.13%
2021-12-31 CN¥2.92 Billion
≈ $427.32 Million
CN¥35.80 Million
≈ $5.24 Million
0.012x -83.03%
2020-12-31 CN¥2.85 Billion
≈ $417.74 Million
CN¥206.21 Million
≈ $30.17 Million
0.072x -77.54%
2019-12-31 CN¥2.38 Billion
≈ $347.78 Million
CN¥764.26 Million
≈ $111.84 Million
0.322x +35.70%
2018-12-31 CN¥1.99 Billion
≈ $291.83 Million
CN¥472.61 Million
≈ $69.16 Million
0.237x +19.17%
2017-12-31 CN¥1.97 Billion
≈ $288.32 Million
CN¥391.81 Million
≈ $57.33 Million
0.199x +9.11%
2016-12-31 CN¥2.25 Billion
≈ $328.53 Million
CN¥409.20 Million
≈ $59.88 Million
0.182x -11.28%
2015-12-31 CN¥2.16 Billion
≈ $315.58 Million
CN¥443.03 Million
≈ $64.83 Million
0.205x -13.86%
2014-12-31 CN¥2.11 Billion
≈ $308.37 Million
CN¥502.57 Million
≈ $73.54 Million
0.238x -19.15%
2013-12-31 CN¥1.93 Billion
≈ $281.97 Million
CN¥568.41 Million
≈ $83.18 Million
0.295x +8.40%
2012-12-31 CN¥1.71 Billion
≈ $249.91 Million
CN¥464.75 Million
≈ $68.01 Million
0.272x -19.89%
2011-12-31 CN¥767.76 Million
≈ $112.35 Million
CN¥260.79 Million
≈ $38.16 Million
0.340x -58.11%
2010-12-31 CN¥453.09 Million
≈ $66.30 Million
CN¥367.38 Million
≈ $53.76 Million
0.811x -70.23%
2009-12-31 CN¥135.17 Million
≈ $19.78 Million
CN¥368.21 Million
≈ $53.88 Million
2.724x +519.97%
2008-12-31 CN¥214.95 Million
≈ $31.45 Million
CN¥94.45 Million
≈ $13.82 Million
0.439x --

About Xizang Haisco Pharmaceutical Group Co Ltd

SHE:002653 China Biotechnology
Market Cap
$11.52 Billion
CN¥78.71 Billion CNY
Market Cap Rank
#2017 Global
#211 in China
Share Price
CN¥70.28
Change (1 day)
-1.84%
52-Week Range
CN¥42.93 - CN¥79.19
All Time High
CN¥79.19
About

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more